Allergan, Inc. (AGN) said that the United States District Court of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd., Apotex, Inc. and Apotex Corp. for seeking to market purported generic versions of Allergan's
As a result, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
For comments and feedback: editorial@rttnews.com